SHENZHEN, China, July 31 /PRNewswire-FirstCall/ - Hard to Treat Diseases,Inc. (HTDS:PK), http://www.htdsmedical.com announced today that itsregistration dossier for MEVAC-DTaP (Diphtheria, Tetanus and AcellularPertussis Combined Vaccine, adsorbed) had passed the preliminary considerationof the experts in Thai FDA. The sample analysis is expected to be completedwithin the next 30 days.
Mr. Terry Yuan CEO of HTDS said (sic) "We welcome the expanded role of themedical team in Serbia. There has been a great synergy between the medicalgroup in Serbia and us here in China, right from day one. I have greatadmiration for the work they are doing which is simply amazing. It is our goaland target to see the fruits of our labour begin to pay off for us and all ofour shareholders.
HTDS was a company acquired by the new management, with the backing of ourfinanciers' under duress, just less than a year ago. Many of HTDS long timeshareholders basically witnessed HTDS share values dwindle down to next tonothing. Our goal is to reverse that trend and we believe we are well underway. We have received a number of inquiries about an open Regulation Dfinancing and filing we did. HTDS is a medical company engaged in both RD andvaccine distribution as its core business. Over the next several weeks andmonths we will be issuing many updates as to what progress the company made.By that we mean, how this financing was used, what equipment was acquired,contracts signed and what assets were acquired, and more importantly theforward strides we made as a company. Our days of being under duress and inperil are well behind us now.
Today, in less than a year we have two very vibrant companies in HTDS. Weare focused, determined and the two companies are working hard and there isgreat synergy and sync between us all. The Mellow Hope division generatesrevenues and steady cash flows that a business is judged upon, and generallyvaluated. Slavica Bio Chem on the other hand is a company whose research anddevelopment can have astronomical growth impact on our whole organization, andour share price, which by all accounts I can safely say continues to be veryundervalued"
Safe Harbor Statement
Information in this filing may contain statements about futureexpectations, plans, prospects or performance of Hard to Treat Diseases, Inc.that constitute forward-looking statements for purposes of the safe harborProvision's under the Private Securities Litigation Reform Act of 1995. Thewords or phrases "can be," "expects," "may affect," "believed," "estimate,""project," and similar words and phrases are intended to identify suchforward-looking statements. HTDS Corporation cautions you that anyforward-looking information provided by or on behalf of Hard to TreatDiseases, Inc. is not a guarantee of future performance. None of theinformation in this filing constitutes or is intended as an offer to sellsecurities or investment advice of any kind. Hard to Treat Diseases, Inc.'sactual results may differ materially from those anticipated in suchforward-looking statements as a result of various important factors, some ofwhich are beyond Hard to Treat Diseases, Inc. 's control. In addition to thosediscussed in Hard to Treat Diseases, Inc.'s press releases, public filings,and statements by Hard to Treat Diseases, Inc.'s management, including, butnot limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency ofits existing capital resources, Hard to Treat Diseases, Inc.'s ability toraise additional capital to fund future operations, HTDS Corporation's abilityto repay its existing indebtedness, the uncertainties involved in estimatingmarket opportunities and, in identifying contracts which match Hard to TreatDiseases, Inc.'s capability to be awarded contracts. All such forward-lookingstatements are current only as of the date on which such statements were made.Hard to Treat Diseases, Inc. does not undertake any obligation to publiclyupdate any forward-looking statement to reflect events or circumstances afterthe date on which any such statement is made or to reflect the occurrence ofunanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please email@example.com; For any corporate matters, please firstname.lastname@example.org, www.htdsmedical.com
SOURCE Hard to Treat Diseases